Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1915 3
1916 1
1956 2
1957 1
1961 8
1962 5
1963 2
1964 1
1965 1
1966 4
1967 6
1968 4
1969 8
1970 9
1971 4
1972 8
1973 12
1974 9
1975 11
1976 9
1977 9
1978 28
1979 20
1980 17
1981 24
1982 16
1983 20
1984 19
1985 31
1986 37
1987 35
1988 35
1989 37
1990 33
1991 32
1992 54
1993 43
1994 44
1995 37
1996 47
1997 39
1998 49
1999 43
2000 58
2001 47
2002 40
2003 46
2004 45
2005 51
2006 46
2007 53
2008 55
2009 45
2010 37
2011 42
2012 60
2013 48
2014 55
2015 65
2016 52
2017 79
2018 81
2019 76
2020 98
2021 50
Text availability
Article attribute
Article type
Publication date

Search Results

1,937 results
Results by year
Filters applied: . Clear all
Page 1
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.
Hiraoka A, Kumada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Yokohama K, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M. Hiraoka A, et al. Among authors: tsuji k. Liver Cancer. 2020 Jan;9(1):73-83. doi: 10.1159/000503031. Epub 2019 Oct 18. Liver Cancer. 2020. PMID: 32071911 Free PMC article.
Chemically Programmable and Switchable CAR-T Therapy.
Qi J, Tsuji K, Hymel D, Burke TR Jr, Hudecek M, Rader C, Peng H. Qi J, et al. Among authors: tsuji k. Angew Chem Int Ed Engl. 2020 Jul 13;59(29):12178-12185. doi: 10.1002/anie.202005432. Epub 2020 May 18. Angew Chem Int Ed Engl. 2020. PMID: 32329959
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: tsuji k. Cancer Med. 2019 Jul;8(8):3719-3728. doi: 10.1002/cam4.2241. Epub 2019 May 24. Cancer Med. 2019. PMID: 31127698 Free PMC article.
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: tsuji k. Oncology. 2019;97(5):277-285. doi: 10.1159/000501281. Epub 2019 Jul 15. Oncology. 2019. PMID: 31307035
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.
Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: tsuji k. Cancer Med. 2019 Jan;8(1):137-146. doi: 10.1002/cam4.1909. Epub 2018 Dec 21. Cancer Med. 2019. PMID: 30575325 Free PMC article.
1,937 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page